Free Trial
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free TGTX Stock Alerts

TG Therapeutics (TGTX) Financials

TG Therapeutics logo
$42.65 +0.11 (+0.26%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$42.58 -0.07 (-0.17%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for TG Therapeutics

Annual Income Statements for TG Therapeutics

This table shows TG Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -63 -78 -118 -173 -173 -279 -348 -224 13 23 447
Consolidated Net Income / (Loss)		 -63 -78 -118 -173 -173 -279 -348 -224 13 23 447
Net Income / (Loss) Continuing Operations		 -63 -78 -118 -173 -173 -279 -348 -224 13 23 447
Total Pre-Tax Income 		-63 -78 -118 -173 -173 -279 -348 -224 13 26 107
Total Operating Income		 -63 -79 -119 -174 -169 -274 -345 -218 21 42 123
Total Gross Profit		 0.15 0.15 0.15 0.15 0.15 0.15 5.90 2.79 220 291 516
Total Revenue		 0.15 0.15 0.15 0.15 0.15 0.15 6.69 2.79 234 329 616
Operating Revenue		 0.15 0.15 0.15 0.15 0.15 0.15 6.69 2.79 234 329 616
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.79 0.00 14 38 101
Operating Cost of Revenue		 - - - - 0.00 0.00 0.79 - 14 38 101
Total Operating Expenses		 63 79 119 175 169 274 351 221 199 249 392
Selling, General & Admin Expense		 16 9.89 16 15 15 108 128 95 123 154 232
Research & Development Expense		 48 69 103 159 154 166 223 125 76 94 160
Total Other Income / (Expense), net		 0.23 0.72 0.24 0.92 -3.82 -5.79 -3.33 -5.50 -7.57 -16 -16
Interest Expense		 - - 0.85 0.88 5.29 6.33 5.64 10 13 24 27
Other Income / (Expense), net		 0.06 0.39 1.08 1.80 1.47 0.54 2.31 4.70 5.04 7.69 11
Income Tax Expense		 - - - - - - 0.00 0.00 0.39 2.21 -340
Basic Earnings per Share		 ($1.38) ($1.60) ($1.91) ($2.30) ($1.96) ($2.42) ($2.63) ($1.65) $0.09 $0.16 $3.10
Weighted Average Basic Shares Outstanding		 45.65M 49.04M 62.07M 75.47M 88.37M 115.33M 132.22M 135.41M 141.96M 145.32M 144.32M
Diluted Earnings per Share		 ($1.38) ($1.60) ($1.91) ($2.30) ($1.96) ($2.42) ($2.63) ($1.65) $0.09 $0.15 $2.77
Weighted Average Diluted Shares Outstanding		 45.65M 49.04M 62.07M 75.47M 88.37M 115.33M 132.22M 135.41M 148.51M 160.34M 161.41M
Weighted Average Basic & Diluted Shares Outstanding		 45.65M 49.04M 62.07M 75.47M 88.37M 115.33M 132.22M 146.36M 154.42M 157.07M 159.69M

Quarterly Income Statements for TG Therapeutics

This table shows TG Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 114 -14 -11 6.88 3.88 23 5.06 28 391 23 20
Consolidated Net Income / (Loss)		 114 -14 -11 6.88 3.88 23 5.06 28 391 23 20
Net Income / (Loss) Continuing Operations		 114 -14 -11 6.88 3.88 23 5.06 28 391 23 20
Total Pre-Tax Income 		114 -14 -11 6.55 4.27 25 5.47 31 26 45 20
Total Operating Income		 115 -12 -9.27 8.82 12 30 8.62 35 29 50 35
Total Gross Profit		 162 34 58 65 75 83 105 122 134 154 171
Total Revenue		 166 44 63 73 84 108 121 141 162 193 205
Operating Revenue		 166 44 63 73 84 108 121 141 162 193 205
Total Cost of Revenue		 3.51 9.77 5.44 8.30 9.34 25 16 19 28 38 34
Operating Cost of Revenue		 3.51 - 5.44 8.30 9.34 - 16 19 28 38 34
Total Operating Expenses		 48 47 67 56 62 53 97 87 104 104 137
Selling, General & Admin Expense		 33 31 35 39 42 39 50 56 63 63 88
Research & Development Expense		 15 17 33 18 20 24 46 32 41 41 48
Total Other Income / (Expense), net		 -0.85 -1.54 -1.41 -2.27 -8.17 -4.50 -3.15 -3.92 -3.46 -5.40 -14
Interest Expense		 3.71 2.43 2.29 3.98 11 6.93 6.76 6.72 6.72 6.53 17
Other Income / (Expense), net		 2.86 0.89 0.88 1.71 2.67 2.44 3.60 2.79 3.27 1.13 2.39
Income Tax Expense		 0.00 0.39 0.03 -0.33 0.39 2.12 0.41 2.73 -365 22 0.59
Basic Earnings per Share		 $0.80 ($0.09) ($0.07) $0.05 $0.03 $0.15 $0.03 $0.19 $2.69 $0.19 $0.14
Weighted Average Basic Shares Outstanding		 142.87M 141.96M 146.21M 144.73M 145.10M 145.32M 146.68M 146.74M 145.42M 144.32M 144.44M
Diluted Earnings per Share		 $0.73 - ($0.07) $0.04 $0.02 - $0.03 $0.17 $2.43 $0.14 $0.12
Weighted Average Diluted Shares Outstanding		 155.87M 148.51M 146.21M 159.42M 160.71M 160.34M 162.77M 162.56M 161.00M 161.41M 160.06M
Weighted Average Basic & Diluted Shares Outstanding		 151.41M 154.42M 154.54M 154.82M 155.67M 157.07M 158.76M 158.67M 158.76M 159.69M 153.08M

Annual Cash Flow Statements for TG Therapeutics

This table details how cash moves in and out of TG Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.65 -30 32 -14 71 441 -255 -197 -9.36 87 -101
Net Cash From Operating Activities		 -45 -63 -94 -129 -133 -215 -296 -176 -31 -41 -25
Net Cash From Continuing Operating Activities		 -45 -62 -94 -129 -133 -215 -296 -176 -31 -41 -25
Net Income / (Loss) Continuing Operations		 -63 -78 -118 -173 -173 -279 -348 -224 13 23 447
Consolidated Net Income / (Loss)		 -63 -78 -118 -173 -173 -279 -348 -224 13 23 447
Depreciation Expense		 0.02 0.06 0.08 0.09 0.10 0.16 0.28 0.30 0.21 0.07 0.06
Amortization Expense		 0.54 0.46 0.19 0.02 0.70 1.11 1.81 1.73 0.35 -4.78 -2.39
Non-Cash Adjustments To Reconcile Net Income		 16 5.33 16 17 14 83 63 45 38 48 73
Changes in Operating Assets and Liabilities, net		 2.07 11 8.44 28 25 -20 -12 0.69 -82 -107 -543
Net Cash From Investing Activities		 -25 27 -8.21 1.18 -0.72 -25 -0.33 -20 -51 -1.04 14
Net Cash From Continuing Investing Activities		 -25 27 -8.21 1.18 -0.72 -25 -0.33 -20 -51 -1.04 14
Purchase of Property, Plant & Equipment		 -0.04 -0.34 -0.00 -0.09 -0.13 -0.36 -0.40 -0.01 0.00 -0.05 -0.21
Purchase of Investments		 -49 -15 -28 -31 -30 -67 -56 -107 -147 -312 -223
Sale and/or Maturity of Investments		 24 42 20 33 29 43 56 87 96 311 238
Net Cash From Financing Activities		 69 5.02 134 114 204 680 41 -0.39 73 129 -90
Net Cash From Continuing Financing Activities		 69 5.02 134 114 204 680 41 -0.39 73 129 -90
Repayment of Debt		 - -0.01 - 0.00 -0.80 0.00 -1.02 -0.98 -0.13 -108 0.00
Repurchase of Common Equity		 - - - - - - - 0.00 0.00 -8.76 -91
Issuance of Debt		 0.10 - 0.00 0.00 30 0.00 70 0.00 25 245 0.00
Issuance of Common Equity		 - - - 0.00 - - 2.22 0.00 46 0.00 0.00
Other Financing Activities, net		 69 5.03 134 114 175 680 -30 0.58 1.53 0.91 1.51
Cash Interest Paid		 - - - - - - 3.47 5.45 8.77 18 24
Cash Income Taxes Paid		 - - - - - - - 0.00 0.00 0.50 7.88

Quarterly Cash Flow Statements for TG Therapeutics

This table details how cash moves in and out of TG Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 54 -58 -17 7.44 113 -16 -48 -3.00 -55 5.08 363
Net Cash From Operating Activities		 84 -13 -8.21 5.54 -12 -26 -29 7.44 -23 20 -18
Net Cash From Continuing Operating Activities		 84 -13 -8.21 5.54 -12 -26 -29 7.44 -23 20 -18
Net Income / (Loss) Continuing Operations		 114 -14 -11 6.88 3.88 23 5.06 28 391 23 20
Consolidated Net Income / (Loss)		 114 -14 -11 6.88 3.88 23 5.06 28 391 23 20
Depreciation Expense		 0.07 0.04 0.03 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.03
Amortization Expense		 0.48 -0.84 -0.98 -1.11 -1.35 -1.34 -0.98 -0.93 -0.44 -0.03 -0.03
Non-Cash Adjustments To Reconcile Net Income		 7.56 9.46 8.92 10 17 13 15 16 19 23 28
Changes in Operating Assets and Liabilities, net		 -38 -7.46 -5.47 -11 -32 -61 -48 -36 -432 -26 -66
Net Cash From Investing Activities		 -30 -45 -9.26 1.77 -9.33 16 -13 -3.99 46 -16 -9.86
Net Cash From Continuing Investing Activities		 -30 -45 -9.26 1.77 -9.33 16 -13 -3.99 46 -16 -9.86
Purchase of Property, Plant & Equipment		 - - 0.00 - - -0.02 -0.03 -0.04 -0.08 -0.07 -0.05
Purchase of Investments		 -56 -68 -83 -70 -102 -58 -93 -53 -31 -46 -21
Sale and/or Maturity of Investments		 26 24 73 71 92 74 80 49 78 30 11
Net Cash From Financing Activities		 0.42 -0.00 0.01 0.14 134 -6.07 -6.10 -6.44 -78 1.06 391
Net Cash From Continuing Financing Activities		 0.42 -0.00 0.01 0.14 134 -6.07 -6.10 -6.44 -78 1.06 391
Repayment of Debt		 - - - - -108 108 0.00 - - - -2.60
Repurchase of Common Equity		 - - 0.00 - - -6.61 -6.12 -6.88 -78 - -100
Issuance of Debt		 - - - - 245 - 0.00 - - - 748
Other Financing Activities, net		 0.42 - 0.01 0.14 0.20 -107 0.02 0.43 - 1.06 -254
Cash Interest Paid		 - 4.84 2.45 2.49 7.11 6.42 6.14 6.10 6.10 5.91 2.39
Cash Income Taxes Paid		 - - - - - - 0.00 - 1.96 0.85 3.44

Annual Balance Sheets for TG Therapeutics

This table presents TG Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 113 55 97 84 163 626 380 194 330 578 1,063
Total Current Assets		 87 51 93 79 149 612 331 168 318 566 631
Cash & Equivalents		 55 25 57 42 113 553 299 102 93 180 79
Short-Term Investments		 22 20 28 27 28 52 16 59 125 131 63
Accounts Receivable		 - - - - - 0.00 1.39 0.00 51 129 306
Inventories, net		 - - - - - - - 0.00 40 110 126
Other Current Assets		 0.31 0.22 0.44 0.44 0.61 1.08 2.88 2.36 9.52 16 58
Plant, Property, & Equipment, net		 0.05 0.33 0.25 0.25 0.28 0.48 0.60 0.31 0.00 0.00 0.00
Total Noncurrent Assets		 27 3.59 3.82 4.33 14 13 48 25 12 11 432
Long-Term Investments		 25 - - - - 0.00 36 12 0.00 0.81 59
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - 0.00 348
Other Noncurrent Operating Assets		 0.17 0.16 - 1.24 11 11 9.89 10 12 11 25
Total Liabilities & Shareholders' Equity		 113 55 97 84 163 626 380 194 330 578 1,063
Total Liabilities		 12 19 30 60 124 106 142 135 169 355 415
Total Current Liabilities		 11 17 28 39 84 88 65 53 54 91 154
Accounts Payable		 9.35 15 26 36 30 37 51 42 38 58 108
Current Deferred Revenue		 0.15 0.15 0.15 - - - - - 0.15 11 21
Current Employee Benefit Liabilities		 0.82 1.39 1.80 2.26 3.80 8.46 10 8.43 12 15 22
Other Current Liabilities		 - - - 0.22 51 20 2.95 2.75 2.93 5.78 3.17
Total Noncurrent Liabilities		 1.37 2.04 2.43 21 40 19 77 82 115 265 261
Long-Term Debt		 - - - 0.00 29 7.72 67 71 100 244 246
Noncurrent Deferred Revenue		 1.37 2.04 2.43 2.38 0.76 0.61 0.46 0.31 6.02 12 8.81
Other Noncurrent Operating Liabilities		 - - 0.00 18 10 10 9.85 10 9.23 8.13 7.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 102 36 67 24 39 519 237 59 161 222 648
Total Preferred & Common Equity		 102 36 67 24 39 519 237 59 161 222 648
Total Common Equity		 102 36 67 24 39 519 237 59 161 222 648
Common Stock		 260 272 422 553 740 1,500 1,566 1,586 1,713 1,761 1,830
Retained Earnings		 -158 -236 -355 -528 -701 -981 -1,329 -1,527 -1,553 -1,529 -1,082
Treasury Stock		 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -8.99 -100

Quarterly Balance Sheets for TG Therapeutics

This table presents TG Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 218 197 221 331 373 401 586 657 703 1,025 1,529
Total Current Assets		 183 185 209 319 361 389 574 645 664 600 1,087
Cash & Equivalents		 110 61 97 151 75 83 196 132 129 74 442
Short-Term Investments		 66 78 48 78 134 134 145 144 123 58 72
Accounts Receivable		 0.00 8.62 17 39 65 84 116 190 232 265 392
Inventories, net		 - 27 30 34 78 81 85 158 155 147 129
Other Current Assets		 2.95 4.46 11 12 8.10 7.05 33 20 25 56 51
Plant, Property, & Equipment, net		 0.38 0.24 0.21 0.13 0.07 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 35 12 12 12 13 12 12 12 39 425 442
Long-Term Investments		 22 0.00 0.00 0.00 1.32 0.95 1.13 1.91 29 49 62
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - 367 344
Other Noncurrent Operating Assets		 10 9.97 9.75 9.55 9.20 11 11 10 10 9.88 36
Total Liabilities & Shareholders' Equity		 218 197 221 331 373 401 586 657 703 1,025 1,529
Total Liabilities		 117 170 180 166 213 224 394 419 426 418 946
Total Current Liabilities		 36 63 73 58 100 109 125 160 172 157 187
Accounts Payable		 30 57 63 40 87 93 101 134 134 112 149
Current Deferred Revenue		 - - - 6.90 3.37 3.37 9.09 17 24 26 17
Current Employee Benefit Liabilities		 4.30 3.22 6.64 8.34 3.60 6.35 10 5.14 11 15 19
Other Current Liabilities		 2.42 2.77 3.08 2.70 5.45 5.47 4.53 4.06 3.35 3.06 2.42
Total Noncurrent Liabilities		 81 107 108 109 114 115 269 259 254 261 759
Long-Term Debt		 70 97 98 99 101 103 244 245 245 245 745
Noncurrent Deferred Revenue		 0.34 0.27 0.23 0.19 3.24 3.74 16 6.60 1.67 8.35 6.86
Other Noncurrent Operating Liabilities		 11 10 9.81 9.52 8.96 8.70 8.42 7.86 7.59 7.31 6.60
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 100 27 40 165 160 178 192 237 276 607 583
Total Preferred & Common Equity		 100 27 40 165 160 178 192 237 276 607 583
Total Common Equity		 100 27 40 165 160 178 192 237 276 607 583
Common Stock		 1,575 1,594 1,655 1,665 1,685 1,734 1,747 1,777 1,794 1,813 1,846
Retained Earnings		 -1,474 -1,566 -1,614 -1,500 -1,525 -1,556 -1,553 -1,524 -1,496 -1,105 -1,062
Treasury Stock		 - -0.23 -0.23 -0.23 -0.23 -0.23 -2.38 -15 -22 -100 -200

Annual Metrics And Ratios for TG Therapeutics

This table displays calculated financial ratios and metrics derived from TG Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 158,759,451.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 158,759,451.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 2.82
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -44 -55 -83 -122 -118 -192 -241 -153 20 38 514
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -117.81% 7.68% 8.21% 57.46%
Earnings before Interest and Taxes (EBIT)		 -63 -79 -118 -173 -168 -273 -342 -214 26 50 134
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -63 -78 -117 -173 -167 -272 -340 -212 26 45 132
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -42 -47 -74 -95 -90 -208 -252 -154 -67 -74 -24
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.03 -9.53 -18 -45 -73 -56 -45 -44 43 155 693
Increase / (Decrease) in Invested Capital		 -2.05 -8.51 -8.65 -27 -28 17 11 1.02 87 112 538
Book Value per Share		 $1.93 $0.66 $0.95 $0.29 $0.39 $3.95 $1.66 $0.40 $1.06 $1.43 $4.08
Tangible Book Value per Share		 $1.92 $0.64 $0.94 $0.28 $0.38 $3.94 $1.65 $0.40 $1.06 $1.43 $4.08
Total Capital		 102 36 67 24 68 549 305 130 261 467 894
Total Debt		 0.21 0.07 0.13 0.00 29 30 68 71 100 244 246
Total Long-Term Debt		 0.00 0.00 0.00 0.00 29 7.72 67 71 100 244 246
Net Debt		 -102 -45 -85 -69 -111 -576 -283 -103 -117 -67 45
Capital Expenditures (CapEx)		 0.04 0.34 0.00 0.09 0.13 0.36 0.40 0.01 0.00 0.05 0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.67 -11 -19 -29 -76 -59 -48 -47 47 165 335
Debt-free Net Working Capital (DFNWC)		 77 34 65 40 65 546 267 115 264 476 477
Net Working Capital (NWC)		 76 34 65 40 65 524 266 115 264 476 477
Net Nonoperating Expense (NNE)		 19 23 35 51 55 88 107 71 7.34 15 66
Net Nonoperating Obligations (NNO)		 -103 -45 -85 -69 -111 -576 -283 -103 -117 -67 45
Total Depreciation and Amortization (D&A)		 0.55 0.52 0.27 0.10 0.80 1.27 2.09 2.03 0.57 -4.71 -2.33
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.38) ($1.60) ($1.91) ($2.30) ($1.96) ($2.42) ($2.63) ($1.46) $0.09 $0.16 $3.10
Adjusted Weighted Average Basic Shares Outstanding		 54.10M 56.91M 75.58M 83.87M 109.40M 140.59M 142.82M 135.41M 141.96M 145.32M 144.32M
Adjusted Diluted Earnings per Share		 ($1.38) ($1.60) ($1.91) ($2.30) ($1.96) ($2.42) ($2.63) ($1.46) $0.09 $0.15 $2.77
Adjusted Weighted Average Diluted Shares Outstanding		 54.10M 56.91M 75.58M 83.87M 109.40M 140.59M 142.82M 135.41M 148.51M 160.34M 161.41M
Adjusted Basic & Diluted Earnings per Share		 ($1.38) ($1.60) ($1.91) ($2.30) ($1.96) ($2.42) ($2.63) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 45.65M 49.04M 62.07M 75.47M 88.37M 115.33M 132.22M 146.36M 154.42M 157.07M 159.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -44 -55 -83 -122 -118 -192 -241 -153 20 38 86
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for TG Therapeutics

This table displays calculated financial ratios and metrics derived from TG Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 158,759,451.00 159,688,256.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 158,759,451.00 159,688,256.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.15 0.12
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 176,298.94% 54,183.95% 713.46% 357.05% -49.41% 146.04% 90.40% 92.13% 92.79% - 69.56%
EBITDA Growth		 450.35% 83.51% 74.14% 121.73% -88.36% 350.48% 220.45% 288.98% 134.07% - 230.52%
EBIT Growth		 444.29% 84.66% 76.94% 123.94% -87.16% 379.29% 245.71% 257.48% 116.09% - 204.15%
NOPAT Growth		 569.00% 83.90% 74.94% 129.60% -90.15% 414.12% 222.96% 243.11% 3,819.42% - 323.55%
Net Income Growth		 418.08% 81.63% 72.71% 114.45% -96.59% 261.84% 147.26% 309.75% 9,974.61% - 290.85%
EPS Growth		 380.77% 0.00% 0.00% 111.76% -97.26% 0.00% 142.86% 325.00% 12,050.00% - 300.00%
Operating Cash Flow Growth		 342.66% 44.66% 86.30% 113.18% -114.58% -94.10% -249.88% 34.32% -89.70% - 37.68%
Free Cash Flow Firm Growth		 203.73% -73.99% -36.56% -1.84% -191.05% 12.26% -100.52% -148.04% -179.41% - -253.54%
Invested Capital Growth		 226.96% 197.19% 419.07% 1,016.85% 172.75% 259.49% 305.07% 289.31% 613.99% - 269.00%
Revenue Q/Q Growth		 931.57% -73.48% 44.36% 15.74% 14.17% 28.98% 11.71% 16.79% 14.57% - 6.41%
EBITDA Q/Q Growth		 372.05% -110.49% 24.67% 201.07% 45.79% 125.65% -63.77% 226.39% -12.27% - -27.97%
EBIT Q/Q Growth		 367.47% -109.86% 27.64% 225.48% 43.43% 114.46% -62.25% 207.86% -13.30% - -27.98%
NOPAT Q/Q Growth		 467.05% -107.61% 25.75% 242.66% 22.10% 142.86% -70.94% 298.10% 1,294.81% - 31.00%
Net Income Q/Q Growth		 339.30% -112.65% 25.73% 164.25% -43.60% 501.31% -78.31% 457.06% 1,286.79% - -14.15%
EPS Q/Q Growth		 314.71% 0.00% 0.00% 0.00% -50.00% 0.00% 0.00% 466.67% 1,329.41% - -14.29%
Operating Cash Flow Q/Q Growth		 299.27% -115.78% 37.87% 167.45% -320.47% -110.09% -11.99% 125.90% -411.36% - -191.02%
Free Cash Flow Firm Q/Q Growth		 191.00% -281.27% 24.55% 18.17% 18.64% -74.69% -72.43% -1.22% 8.35% - -0.56%
Invested Capital Q/Q Growth		 611.23% 24.90% 16.74% 23.00% 52.08% 64.62% 31.54% 18.21% 178.92% - 8.63%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 97.88% 77.79% 91.43% 88.70% 100.00% 77.13% 87.14% 86.58% 82.63% - 83.65%
EBITDA Margin		 71.28% -28.19% -14.71% 12.85% 16.41% 28.70% 9.31% 26.01% 19.92% - 18.14%
Operating Margin		 69.22% -28.39% -14.60% 12.00% 14.82% 27.68% 7.13% 24.69% 18.16% - 16.98%
EBIT Margin		 70.95% -26.37% -13.22% 14.33% 18.00% 29.93% 10.12% 26.66% 20.18% - 18.14%
Profit (Net Income) Margin		 68.71% -32.79% -16.87% 9.36% 4.63% 21.57% 4.19% 19.97% 241.73% - 9.65%
Tax Burden Percent		 100.00% 102.78% 100.27% 105.01% 90.91% 91.66% 92.54% 91.16% 1,508.72% - 97.12%
Interest Burden Percent		 96.84% 120.97% 127.27% 62.22% 28.26% 78.60% 44.73% 82.16% 79.40% - 54.77%
Effective Tax Rate		 0.00% 0.00% 0.00% -5.01% 9.09% 8.34% 7.46% 8.84% -1,408.72% - 2.88%
Return on Invested Capital (ROIC)		 3,584.90% 0.00% -171.19% 158.43% 55.47% 84.29% 20.07% 67.47% 380.30% - 24.16%
ROIC Less NNEP Spread (ROIC-NNEP)		 3,585.56% 0.00% -165.68% 161.35% 61.97% 88.75% 24.15% 72.20% 696.24% - 3.51%
Return on Net Nonoperating Assets (RNNOA)		 -3,486.49% 0.00% 135.15% -120.53% -39.63% -42.83% -8.70% -24.03% -28.75% - 0.58%
Return on Equity (ROE)		 98.41% 11.57% -36.04% 37.90% 15.84% 41.46% 11.37% 43.44% 351.55% - 24.74%
Cash Return on Invested Capital (CROIC)		 -217.19% -156.46% -36.23% 53.45% -93.24% -74.27% -76.66% -66.42% -14.08% - 3.40%
Operating Return on Assets (OROA)		 49.05% -23.56% -13.40% 15.98% 10.40% 21.71% 7.59% 21.94% 13.32% - 11.63%
Return on Assets (ROA)		 47.51% -29.29% -17.10% 10.44% 2.67% 15.64% 3.14% 16.43% 159.62% - 6.19%
Return on Common Equity (ROCE)		 98.41% 11.57% -36.04% 37.90% 15.84% 41.46% 11.37% 43.44% 351.55% - 24.74%
Return on Equity Simple (ROE_SIMPLE)		 -15.72% 0.00% 25.73% 53.89% -7.48% 0.00% 16.50% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 115 -8.74 -6.49 9.26 11 27 7.98 32 443 26 34
NOPAT Margin		 69.22% -19.88% -10.22% 12.60% 13.48% 25.38% 6.60% 22.50% 273.97% - 16.49%
Net Nonoperating Expense Percent (NNEP)		 -0.66% -5.15% -5.51% -2.92% -6.50% -4.46% -4.08% -4.73% -315.94% - 20.65%
Return On Investment Capital (ROIC_SIMPLE)		 - -3.35% - - - 5.88% 1.66% 6.09% 51.97% 2.89% 2.54%
Cost of Revenue to Revenue		 2.12% 22.21% 8.57% 11.30% 0.00% 22.87% 12.86% 13.42% 17.37% - 16.35%
SG&A Expenses to Revenue		 19.76% 70.85% 54.48% 52.80% 50.03% 36.01% 41.65% 39.38% 39.19% - 43.05%
R&D to Revenue		 8.90% 39.68% 51.55% 23.90% 24.01% 22.07% 38.36% 22.52% 25.28% - 23.62%
Operating Expenses to Revenue		 28.66% 106.19% 106.03% 76.70% 85.18% 49.45% 80.01% 61.90% 64.47% - 66.67%
Earnings before Interest and Taxes (EBIT)		 118 -12 -8.39 11 15 32 12 38 33 52 37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 118 -12 -9.34 9.44 14 31 11 37 32 52 37
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 7.66 16.11 14.67 15.48 18.85 21.07 26.10 20.67 9.44 - 9.10
Price to Tangible Book Value (P/TBV)		 7.70 16.11 14.74 15.48 18.85 21.07 26.10 20.67 9.44 - 9.10
Price to Revenue (P/Rev)		 6.65 11.07 8.12 7.93 13.68 14.24 16.03 12.58 10.78 - 7.57
Price to Earnings (P/E)		 0.00 204.08 57.01 28.73 0.00 200.38 158.19 94.51 12.81 - 11.48
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.49% 1.75% 3.48% 0.00% 0.50% 0.63% 1.06% 7.81% - 8.71%
Enterprise Value to Invested Capital (EV/IC)		 32.79 57.26 44.49 42.54 37.42 29.80 30.21 23.56 8.62 - 7.28
Enterprise Value to Revenue (EV/Rev)		 5.96 10.57 7.74 7.60 13.31 14.04 15.94 12.51 10.90 - 7.82
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 94.07 42.24 24.87 2,406.63 102.82 94.04 61.20 52.12 - 34.71
Enterprise Value to EBIT (EV/EBIT)		 0.00 96.14 41.71 24.34 624.37 93.07 87.70 58.33 50.46 - 34.41
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 123.33 46.77 25.88 0.00 120.56 109.78 72.32 11.06 - 9.69
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 110.39 38.83 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 79.59 0.00 0.00 0.00 0.00 0.00 - 336.81
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.60 0.62 0.63 0.58 1.27 1.10 1.03 0.89 0.40 - 1.28
Long-Term Debt to Equity		 0.60 0.62 0.63 0.58 1.27 1.10 1.03 0.89 0.40 - 1.28
Financial Leverage		 -0.97 -1.01 -0.82 -0.75 -0.64 -0.48 -0.36 -0.33 -0.04 - 0.17
Leverage Ratio		 2.07 2.39 3.04 2.85 2.57 2.37 2.59 2.43 2.02 - 2.66
Compound Leverage Factor		 2.00 2.89 3.87 1.78 0.73 1.86 1.16 2.00 1.60 - 1.46
Debt to Total Capital		 37.51% 38.42% 38.76% 36.61% 55.96% 52.36% 50.77% 46.99% 28.78% - 56.10%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 37.51% 38.42% 38.76% 36.61% 55.96% 52.36% 50.77% 46.99% 28.78% - 56.10%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 62.49% 61.58% 61.24% 63.39% 44.04% 47.64% 49.23% 53.01% 71.22% - 43.90%
Debt to EBITDA		 -8.94 3.82 1.91 0.97 166.77 5.44 3.74 2.64 2.21 - 4.72
Net Debt to EBITDA		 11.77 -4.47 -2.07 -1.09 -66.95 -1.50 -0.51 -0.38 0.58 - 1.07
Long-Term Debt to EBITDA		 -8.94 3.82 1.91 0.97 166.77 5.44 3.74 2.64 2.21 - 4.72
Debt to NOPAT		 -7.46 5.00 2.12 1.01 -690.69 6.38 4.36 3.12 0.47 - 1.32
Net Debt to NOPAT		 9.82 -5.86 -2.29 -1.14 277.25 -1.76 -0.60 -0.45 0.12 - 0.30
Long-Term Debt to NOPAT		 -7.46 5.00 2.12 1.01 -690.69 6.38 4.36 3.12 0.47 - 1.32
Altman Z-Score		 0.90 4.14 2.43 3.73 3.26 5.95 7.15 6.73 7.86 - 3.64
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.53 5.92 3.62 3.58 4.59 6.25 4.02 3.86 3.82 - 5.81
Quick Ratio		 4.65 5.00 2.76 2.77 3.65 4.85 2.91 2.81 2.53 - 4.84
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 53 -96 -73 -59 -48 -84 -146 -147 -135 -512 -515
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% -122,100.00% -114,860.00% 17,704.76% -28,941.25% - -35,086.27%
Free Cash Flow to Firm to Interest Expense		 14.29 -39.58 -31.73 -14.94 -4.46 -12.18 -21.54 -21.94 -20.09 - -30.60
Operating Cash Flow to Interest Expense		 22.54 -5.43 -3.59 1.39 -1.13 -3.70 -4.25 1.11 -3.44 - -1.06
Operating Cash Flow Less CapEx to Interest Expense		 22.54 -5.43 -3.59 1.39 -1.13 -3.70 -4.25 1.10 -3.46 - -1.07
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.69 0.89 1.01 1.11 0.58 0.73 0.75 0.82 0.66 - 0.64
Accounts Receivable Turnover		 0.00 0.00 7.86 6.86 3.42 3.65 3.03 2.88 2.79 - 2.41
Inventory Turnover		 0.00 0.00 0.36 0.48 0.40 0.51 0.41 0.50 0.67 - 0.83
Fixed Asset Turnover		 745.67 0.00 1,909.79 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.13 0.35 0.26 0.35 0.33 0.80 0.44 0.52 0.73 - 0.84
Days Sales Outstanding (DSO)		 0.00 0.00 46.43 53.21 106.86 100.00 120.49 126.66 130.76 - 151.70
Days Inventory Outstanding (DIO)		 0.00 0.00 1,023.33 752.97 917.72 712.63 884.51 728.66 542.13 - 441.00
Days Payable Outstanding (DPO)		 2,900.42 1,039.52 1,407.71 1,056.52 1,095.68 458.87 830.87 701.07 500.28 - 434.83
Cash Conversion Cycle (CCC)		 -2,900.42 -1,039.52 -337.96 -250.34 -71.10 353.76 174.13 154.24 172.61 - 157.87
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 35 43 50 62 94 155 204 241 672 693 752
Invested Capital Turnover		 51.79 -374.46 16.75 12.57 4.12 3.32 3.04 3.00 1.39 - 1.46
Increase / (Decrease) in Invested Capital		 62 87 66 69 60 112 154 179 578 538 548
Enterprise Value (EV)		 1,132 2,469 2,239 2,634 3,523 4,618 6,160 5,678 5,797 - 5,474
Market Capitalization		 1,262 2,586 2,349 2,749 3,621 4,686 6,193 5,714 5,732 - 5,305
Book Value per Share		 $1.09 $1.06 $1.04 $1.15 $1.24 $1.43 $1.51 $1.74 $3.83 $4.08 $3.65
Tangible Book Value per Share		 $1.09 $1.06 $1.03 $1.15 $1.24 $1.43 $1.51 $1.74 $3.83 $4.08 $3.65
Total Capital		 264 261 261 280 436 467 482 521 853 894 1,328
Total Debt		 99 100 101 103 244 244 245 245 245 246 745
Total Long-Term Debt		 99 100 101 103 244 244 245 245 245 246 745
Net Debt		 -130 -117 -110 -116 -98 -67 -33 -35 65 45 169
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.04 0.08 0.07 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 32 47 51 63 108 165 208 240 311 335 385
Debt-free Net Working Capital (DFNWC)		 261 264 261 280 449 476 484 492 443 477 900
Net Working Capital (NWC)		 261 264 261 280 449 476 484 492 443 477 900
Net Nonoperating Expense (NNE)		 0.85 5.68 4.22 2.38 7.42 4.12 2.92 3.58 52 2.76 14
Net Nonoperating Obligations (NNO)		 -130 -117 -110 -116 -98 -67 -33 -35 65 45 169
Total Depreciation and Amortization (D&A)		 0.55 -0.80 -0.95 -1.09 -1.34 -1.33 -0.98 -0.92 -0.42 -0.01 -0.00
Debt-free, Cash-free Net Working Capital to Revenue		 17.01% 19.99% 17.67% 18.24% 40.75% 50.05% 53.85% 52.90% 58.54% - 55.03%
Debt-free Net Working Capital to Revenue		 137.76% 113.08% 90.17% 80.90% 169.55% 144.58% 125.34% 108.37% 83.28% - 128.49%
Net Working Capital to Revenue		 137.76% 113.08% 90.17% 80.90% 169.55% 144.58% 125.34% 108.37% 83.28% - 128.49%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.80 ($0.09) ($0.07) $0.05 $0.03 $0.15 $0.03 $0.19 $2.69 $0.19 $0.14
Adjusted Weighted Average Basic Shares Outstanding		 142.87M 141.96M 146.21M 144.73M 145.10M 145.32M 146.68M 146.74M 145.42M 144.32M 144.44M
Adjusted Diluted Earnings per Share		 $0.73 $0.00 $0.00 $0.04 $0.02 $0.00 $0.03 $0.17 $2.43 $0.14 $0.12
Adjusted Weighted Average Diluted Shares Outstanding		 155.87M 148.51M 154.54M 159.42M 160.71M 160.34M 162.77M 162.56M 161.00M 161.41M 160.06M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 151.41M 154.42M 154.54M 154.82M 155.67M 157.07M 158.76M 158.67M 158.76M 159.69M 153.08M
Normalized Net Operating Profit after Tax (NOPAT)		 80 -8.74 -6.49 6.17 11 27 7.98 32 21 26 34
Normalized NOPAT Margin		 48.46% -19.88% -10.22% 8.40% 13.48% 25.38% 6.60% 22.50% 12.71% - 16.49%
Pre Tax Income Margin		 68.71% -31.90% -16.82% 8.92% 5.09% 23.53% 4.52% 21.91% 16.02% - 9.94%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 31.68 -4.77 -3.67 2.65 1.39 4.67 1.81 5.60 4.85 - 2.21
NOPAT to Interest Expense		 30.91 -3.60 -2.84 2.33 1.04 3.96 1.18 4.73 65.92 - 2.01
EBIT Less CapEx to Interest Expense		 31.68 -4.77 -3.67 2.65 1.39 4.67 1.81 5.60 4.84 - 2.21
NOPAT Less CapEx to Interest Expense		 30.91 -3.60 -2.84 2.33 1.04 3.96 1.18 4.72 65.91 - 2.01
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 37.46% 38.02% 35.99% 21.87% - 40.08%

Financials Breakdown Chart

Key Financial Trends

Here is a concise, investor-focused read on TG Therapeutics (TGTX) using the last four years of quarterly data provided. The focus is on revenue, profitability, cash flow, and balance sheet health to help gauge the company’s trajectory and risk factors.

  • Revenue momentum improving: Q4 2025 revenue reached 192,574,000, up from 108,185,000 in Q4 2024, suggesting an improving top line over time.
  • Strong gross margins maintained in the mid-to-high 80% range across recent quarters (e.g., Q1 2025 ~87%, Q2 2025 ~86–87%, Q3 2025 ~82–83%, Q4 2025 ~80%), indicating solid product profitability relative to cost of goods sold.
  • Operating profitability improving: Operating income was positive in every 2025 quarter, with Q4 2025 at about 50,494,000 and Q2 2025 at 34,843,000, highlighting a strengthening core business.
  • Cash flow from operating activities turning positive in parts of 2025: Net cash from continuing operating activities was 7,436,000 in Q2 2025 and 19,660,000 in Q4 2025, signaling improving cash generation from operations.
  • Liquidity remains solid: As of Q3 2025, Total Current Assets were 599,765,000 and Total Current Liabilities 156,810,000, yielding a current ratio around 3.8x, indicating good short-term liquidity.
  • Equity base strengthened: Total Common Equity stood at 607,218,000 in Q3 2025, supported by common stock activity and retained earnings, strengthening the balance sheet base.
  • One-time tax benefit driving large profits in Q3 2025: Net income for continuing operations in Q3 2025 shows a substantial jump (390,895,000) largely due to a negative income tax expense (tax benefit) of 364,986,000, a likely one-off item rather than a sustainable earnings signal.
  • Elevated operating expenses: Research & Development and selling, general, & administrative expenses remain high (e.g., R&D around 41–46M and SG&A around 62–63M in recent quarters), reflecting ongoing investment in the pipeline rather than immediate earnings leverage.
  • Cash flow volatility and some Q-cash burn: Q3 2025 CFO was negative (approximately -23,153,000) and the quarterly net cash from operating activities was negative in several periods, indicating intermittent cash-burn during the period of higher investment and pipeline development.
  • Debt load persists: Long-Term Debt around 245,000,000 and Total Liabilities around 417,806,000 (Q3 2025) imply a meaningful debt burden and ongoing interest obligations, which could pressure near-term cash flow if growth catalysts don’t materialize as expected.

Takeaways for investors

TG Therapeutics shows improving revenue and solid gross margins in 2025, with several quarters posting positive operating income and improving cash flow from operations. The balance sheet appears liquidity-rich in the near term, and equity has been strengthened through new issuances. However, earnings in 2025 have been helped by a notable one-off tax benefit in Q3 2025, and operating cash flow has shown volatility in some periods. Elevated R&D and SG&A expenses indicate substantial ongoing investment in the company’s pipeline, and the company carries a meaningful debt load. Watching the sustainability of profitability beyond the one-off tax benefit, continued cash flow strength, and progress on pipeline milestones will be key near-term risk factors to monitor.

05/14/26 05:14 AM ETAI Generated. May Contain Errors.

TG Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, TG Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

TG Therapeutics' net income appears to be on a downward trend, with a most recent value of $447.18 million in 2025, falling from -$62.95 million in 2015. The previous period was $23.38 million in 2024. Find out what analysts predict for TG Therapeutics in the coming months.

TG Therapeutics' total operating income in 2025 was $123.32 million, based on the following breakdown:
  • Total Gross Profit: $515.57 million
  • Total Operating Expenses: $392.25 million

Over the last 10 years, TG Therapeutics' total revenue changed from $152.38 thousand in 2015 to $616.29 million in 2025, a change of 404,338.2%.

TG Therapeutics' total liabilities were at $415.23 million at the end of 2025, a 16.9% increase from 2024, and a 3,389.4% increase since 2015.

In the past 10 years, TG Therapeutics' cash and equivalents has ranged from $25.03 million in 2016 to $553.44 million in 2020, and is currently $79.15 million as of their latest financial filing in 2025.

Over the last 10 years, TG Therapeutics' book value per share changed from 1.93 in 2015 to 4.08 in 2025, a change of 111.1%.


Related Companies

Financial statements for NASDAQ:TGTX last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Is this AI lab Elon’s SpaceX lifeline?
Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...
Chaikin Analytics | Sponsoredtc pixel
The one number Musk can't hide in the S-1
When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Collect $1,170 a month from silver
I've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...
Investors Alley | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
SpaceX IPO Warning: Before you buy any SpaceX shares, read this.
The SpaceX IPO is valued at $1.75 trillion - but buying shares directly may not be the strongest play availabl...
Weiss Ratings | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel